GoldenGolden
20/20 GeneSystems

20/20 GeneSystems

Biotechnology company providing protein analysis tools and commercializing diagnostic tests

20/20 GeneSystems develops and promotes a proteomics product line providing tools for protein analysis for drug companies, biodefense specialists and life sciences research. The company develops and commercializes proprietary diagnostics tests for cancer and infectious disease.

In March 20, 2020, during the COVID-19 pandemic, 20/20 GeneSystems began taking orders for its diagnostic test CoronaCheck COVID-19 Rapid Antibody Test. The tests are chromatographic immunoassays that test a drop of blood in a similar configuration to a pregnancy test. The test detects IgM and IgG antibodies to SARS-CoV-2 which causes COVID-19. In patients infected with the novel coronavirus, the IgM antibody rises within 1 week of infection and IgG withing 14 days. The test which gives a result in 15 mintues is CE approved and used in European countries. 20/20 is requesting Emergency Use Authorization (EUA) from the FDA and is already available to US based public health providers, hospitals, urgent care centersm and occupational health providers. In an evaluation in China on 760 clinical samples, the manufacturers reported 97.2% sensitivity and 92% specificity.

Timeline

January 2016
20/20 GeneSystems raises a $4,500,000 series A round.
September 2012
20/20 GeneSystems raises a $150,000 seed round from Maryland Venture Fund.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
20/20 GeneSystems, Seed Round, September 2012
150,000
September 2012
3 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.